Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Siris Medical Announces Release of PlanMD™ 2.0 with Powerful User-Driven Enhancements

January 22, 2019 GMT

SAN FRANCISCO--(BUSINESS WIRE)--Jan 22, 2019--Siris Medical, Inc., headquartered in Silicon Valley and Boston, today announced the commercial release of PlanMD™ 2.0, an update of the first AI-powered decision support software for radiation oncologists. PlanMD enables radiation oncology clinical teams to leverage patient data and artificial intelligence to make better treatment decisions. PlanMD is the first and only tool that enables the physician to see the effect of editing contours in real-time, without re-optimizing or replanning. PlanMD complements Siris Medical’s QuickMatch ™ software, which accelerates the treatment planning process by using artificial intelligence to quickly identify the most similar cases previously treated to inform planning decisions and help reduce dose to critical structures.

PlanMD 2.0 enhancements came primarily from input received from radiation oncologists who are the tool’s primary users. These physicians are busy, so the new version is designed to make the tool even faster and easier to use. New precision display functionality allows for greater efficiency and accuracy in structure evaluation and contouring, for both tumor and critical organs. More powerful and granular contour exploration functionality also permits faster insights into the impacts of contouring changes on dose. And a host of smaller, user-driven changes all combine to make PlanMD v2.0 even simpler and faster to use.

Dr. Marc Nash, Chief Medical Officer of Siris Medical and a UCSF-trained, board-certified radiation oncologist noted, “While the underlying prediction algorithms have performed well from the very beginning, it is only through extensive input from practicing radiation oncologists that we can truly ensure the ease of use and rapid results that busy clinicians demand. We are proud to count some of the nation’s leading cancer centers and radiation oncologists as our customers, and their feedback has helped us build an even better, easier to use clinical decision support tool to help physicians in their battle against cancer.”

About PlanMD and the InsightRT Software Suite

The InsightRT Software Suite includes both the QuickMatch (with multi-modality) and PlanMD software modules. QuickMatch and PlanMD together enable a thorough and rapid evaluation of radiation therapy treatment options. The PlanMD module enables clinicians to explore dose predictions based on different contours without having to re-optimize the treatment plan for each scenario considered. QuickMatch enables exploration of the dosimetric tradeoffs inherent with those contours based on predictions developed from a vast database of previously treated patients. The InsightRT software suite is the only artificial intelligence based decision support product on the market for radiation treatment planning and the first to offer physicians the opportunity to see the impact of recontouring on prescriptive doses without having to re-optimize the treatment plan for every scenario.

About Siris Medical

Siris Medical empowers clinicians to efficiently make high-quality radiation treatment decisions through its proprietary artificial intelligence platform. Please visit www.siris-medical.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005848/en/

CONTACT: Colin Carpenter, President and CEO, Siris Medical, Inc

Telephone: (650) 394-5161




SOURCE: Siris Medical, Inc.

Copyright Business Wire 2019.

PUB: 01/22/2019 02:47 PM/DISC: 01/22/2019 02:47 PM